The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement



ImmunoCellular Therapeutics Ltd (IMUC)

ImmunoCellular Therapeutics is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Co.'s clinical product candidates include: ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme, a lethal type of brain cancer; ICT-140, which is a DC immunotherapy that targets seven tumor-associated antigens expressed on ovarian cancer cells; and ICT-121, which specifically targets CD133, a cancer stem cell marker that is in a variety of solid tumors, including ovarian, pancreatic, and breast cancers.

IMUC — Key Stats (updated Wed., Oct. 17, 10:21 AM)
Company Name:  ImmunoCellular Therapeutics Ltd
Website:  www.imuc.com
Sector:  Biotechnology
IMUC — News
IMUC — Price Chart
April 20, 2024  •  10:00 AM Eastern
Latest Market News Video


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
IMUC — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree IMUC Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite
IMUC — Performance

ImmunoCellular Therapeutics Ltd (IMUC) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.